Grifols (Grifols) Days Sales Outstanding

: 38.50 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

Grifols's average Accounts Receivable for the three months ended in Dec. 2023 was $814 Mil. Grifols's Revenue for the three months ended in Dec. 2023 was $1,930 Mil. Hence, Grifols's Days Sales Outstanding for the three months ended in Dec. 2023 was 38.50.

The historical rank and industry rank for Grifols's Days Sales Outstanding or its related term are showing as below:

GRFS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.59 Med: 30.75 Max: 53.08
Current: 53.08

During the past 13 years, Grifols's highest Days Sales Outstanding was 53.08. The lowest was 22.59. And the median was 30.75.

GRFS's Days Sales Outstanding is ranked better than
68.37% of 999 companies
in the Drug Manufacturers industry
Industry Median: 71.93 vs GRFS: 53.08

Grifols's Days Sales Outstanding increased from Sep. 2022 (37.59) to Dec. 2023 (38.50).

Grifols Days Sales Outstanding Historical Data

The historical data trend for Grifols's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

23.10

24.64

31.25

32.19

34.23

Grifols Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Days Sales Outstanding																37.59	32.43	38.86	48.57	38.50

Competitive Comparison

For the Drug Manufacturers - General subindustry, Grifols's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grifols Days Sales Outstanding Distribution

For the Drug Manufacturers industry and Healthcare sector, Grifols's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Grifols's Days Sales Outstanding falls into.

Grifols Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Grifols's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (644.797	+	703.504)	/	2 )	/	7188.634	*	365
=	674.1505					/	7188.634	*	365
=	34.23

Grifols's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (925.003	+	703.504)	/	2 )	/	1929.715	*	365 / 4
=	814.2535					/	1929.715	*	365 / 4
=	38.50

Grifols (NAS:GRFS) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Grifols Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Grifols's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols (Grifols) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GIFLF:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain G0F0:Germany G0F:Germany G0FB:Germany OZTA:Germany OZTA:Germany G0FB:Germany

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.